glioblastoma cells

Clinical trial explores new glioblastoma treatment regimen

On average, a patient with glioblastoma lives for only about a year after diagnosis. In a new clinical trial, CCR researchers will test whether a combination of a vaccine made from the patient’s tumor with another immunotherapy treatment can increase survival rates. Read more...

 

Zbigniew Dauter receives Patterson Award from American Crystallographic Association

Posted: May 26, 2017

Zbigniew Dauter, Ph.D., Senior Investigator in the Macromolecular Crystallography Laboratory, is the 2017 recipient of the Patterson Award from the American Crystallographic Association. The award is given “to recognize and encourage outstanding research in the structure of matter by diffraction methods, including significant contributions to the methodology of structure determination and/or innovative application of diffraction methods and/or elucidation of biological, chemical, geological or physical phenomena using new structural information.”

Zbigniew Dauter receives Patterson Award from American Crystallographic Association

Not slowing down

Posted: May 19, 2017

Nine and-a-half-year-old Travis Carpenter gets a lot of speeding tickets. (He stresses that “and-a-half” part, too). These speeding tickets don’t come from a law enforcement officer but Jesse, one of his nurses at the NIH Clinical Center. Travis uses a power chair that he’s adorned with racing stickers, and his speeding tickets come from him zooming down the Clinical Center’s hallways, dodging the steady traffic of doctors, nurses, patients and families. He loves all things racing, NASCAR and pit crews. Neurofibromatosis type 1 isn’t slowing him down. Read more...

Not slowing down

A Conversation with Kristy and Jane

Posted: May 17, 2017

Jane has been coming to the NIH Clinical Center for treatment for neurofibromatosis type 1 (NF1) since she was three years old. She is currently enrolled in a trial that tests Selumetinib, a MEK inhibitor, and her tumor is now 30.7 percent smaller than when she first started this trial three years ago. Her diagnosis has changed the lives of her family but has also given them new passions and perseverance. Read more...

A Conversation with Kristy and Jane

Clinical trial studies new therapy in children and adults with neurofibromatosis-related GIST

Posted: May 15, 2017

A new clinical trial studies how treatment with a protein kinase inhibitor effects NF1-related GIST in children and young adults. Learn more...

Clinical trial studies new therapy in children and adults with neurofibromatosis-related GIST

Richard Hodes receives Lifetime Achievement Award from the American Association of Immunologists

Posted: May 12, 2017

Richard Hodes, M.D., Senior Investigator in the Experimental Immunology Branch and Director of the National Institute on Aging, was awarded the Lifetime Achievement Award from the American Association of Immunologists (AAI) on Friday, May 12, 2017. According to the AAI website, “the AAI Lifetime Achievement Award is the highest honor bestowed by the AAI Council upon an AAI member. This award recognizes a deserving member for a career of scientific achievement and for contributions to AAI and fellow immunologists.”

Richard Hodes receives Lifetime Achievement Award from the American Association of Immunologists

Researchers identify potential therapeutic targets for a rare childhood cancer

Posted: May 11, 2017

CCR researchers have identified the mechanism behind a rare but extremely aggressive childhood cancer called alveolar rhabdomyosarcoma (ARMS) and have pinpointed a potential drug target for its treatment. Learn more...

Researchers identify potential therapeutic targets for a rare childhood cancer

Clinical trial shows safety and effectiveness of new combination immunotherapy for advanced liver cancer

Posted: May 8, 2017

A recently completed phase I clinical trial at the NIH Clinical Center in Bethesda, Maryland, demonstrates that a combination of two immunotherapy drugs to target hepatocellular carcinoma (HCC) was well-tolerated and shrunk tumors in a larger percentage of patients than the standard monotherapy.  Read more...

Clinical trial shows safety and effectiveness of new combination immunotherapy for advanced liver cancer

NCI RNA Biology 2017 symposium recap

Posted: May 3, 2017

The recent discovery of new classes of RNAs and the demonstration that alterations in RNA metabolism underlie numerous human cancers have resulted in enormous interest among CCR investigators in RNA biology. In order to share the latest research in this exciting field, the CCR Initiative in RNA Biology held its second international symposium April 23-24, 2017, in Natcher Auditorium. Learn more...

NCI RNA Biology 2017 symposium recap

New clinical trial studies two-part treatment for patients with gastric cancer

Posted: May 1, 2017

A new clinical trial is open to test a two-part treatment for stomach cancer that has spread to the peritoneum.
Learn more...

New clinical trial studies two-part treatment for patients with gastric cancer

New clinical trial opens to determine safety and efficacy of PROSTVAC, nivolumab and ipilimumab in men with localized prostate cancer

Posted: Apr 24, 2017

A new study is now open to evaluate the safety and effectiveness of a treatment regimen that combines PROSTVAC with ipilimumab and/or nivolumab in men with localized prostate cancer who have elected to undergo surgical resection (prostatectomy).  Learn more...

New clinical trial opens to determine safety and efficacy of PROSTVAC, nivolumab and ipilimumab in men with localized prostate cancer

Pages